SCHEMBL4073956

SCHEMBL4073956

Cc1cc(OCCCO)cc(C)c1[SiH](C(C)C)C(C)C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TP53 P04637 3/20 0.41
▸ MAPK1 P28482 1/20 0.41
▸ POLB P06746 2/20 0.41
▸ TSHR P16473 2/20 0.41
▸ CYP1A2 P05177 1/20 0.41
▸ CYP2D6 P10635 1/20 0.41
▸ CYP2C19 P33261 1/20 0.41
▸ ALOX15 P16050 1/20 0.37
▸ LMNA P02545 2/20 0.36
▸ MCL1 Q07820 2/20 0.36
▸ THRA P10827 2/20 0.36
▸ THRB P10828 2/20 0.36
▸ GAA P10253 1/20 0.35
▸ ALDH1A1 P00352 3/20 0.33
▸ KDM4E B2RXH2 2/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ CARM1 Q86X55 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ MAPT P10636 1/20 0.32
▸ HPGD P15428 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4072199 0.79 MCL1 (0.62) MAPK1POLBTSHRLMNAMCL1
SCHEMBL14186840 0.77 TP53 (0.51) TP53MAPK1POLBTSHRCYP1A2
SCHEMBL8462273 0.76 TP53 (0.46) TP53MAPK1POLBTSHRCYP1A2
SCHEMBL78064 0.74 ALDH1A1 (0.47) TP53MAPK1POLBTSHRCYP1A2
SCHEMBL25231418 0.74 TP53 (0.45) TP53MAPK1POLBTSHRCYP1A2
SCHEMBL2759034 0.72 ALDH1A1 (0.44) TP53MAPK1POLBTSHRCYP1A2
SCHEMBL3242725 0.71 TP53 (0.62) TP53MAPK1POLBTSHRCYP1A2
SCHEMBL8437066 0.70 TP53 (0.46) TP53MAPK1MCL1GAACARM1
SCHEMBL6459850 0.69 TP53 (0.47) TP53MAPK1POLBTSHRCYP1A2
SCHEMBL12003957 0.68 TP53 (0.42) TP53MAPK1POLBTSHRCYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2074135-A2 SILICON DERIVATIVES FOR PET IMAGING Bayer Schering Pharma AG (DE) 2009-07-01 — — EP disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 — — US disclosed
US-20090035215-A1 RADIOFLUORINATION BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2009-02-05 — — US disclosed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 — — WO disclosed
WO-2008040441-A2 SILICON DERIVATIVES FOR PET IMAGING BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090035215-A1 RADIOFLUORINATION AFF2, AFF1, NUTF2 TP53 1132/4885MAPK1 2960/4885POLB 2590/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback